MedicaidCoverageMedium impact
KMAP BULLETIN: Preferred Drug List Update – August 2026
Kansas Medicaid (KanCare)·KS · Pharmacy·Pharmacy
Effective date
Aug 1, 2026
We identified it
Aug 7, 2026
Summary
Effective August 1, 2026, KMAP is reclassifying 9 medications as Non-Preferred under the Kansas Medicaid Preferred Drug List. These include atomoxetine oral solution, loratadine chewable tablets, multiple denosumab formulations, avatrombopag formulations, and rilzabrutinib. Affected claims will require prior authorization or may result in higher patient cost-sharing when non-preferred drugs are dispensed.
Action Required
By July 15, 2026: Billing and pharmacy teams must update all drug formulary references and prior authorization protocols in the billing system to flag these 9 medications as non-preferred for KMAP beneficiaries. Communicate to prescribing providers that atomoxetine oral solution, loratadine chewable tablets, Bilprevda, Bomyntra, Bildyos, Conexxence, Doptelet, Doptelet Sprinkle, and Wayrilz require prior authorization or preferred alternatives before dispensing. Update pharmacy benefit manager (PBM) interfaces and EMR clinical alerts. Monitor the KanCare Open Claims Resolution Log for MCO-specific implementation dates, as individual MCOs may implement on different timelines. Failure to obtain prior authorization may result in claim denials or patient responsibility for non-covered amounts.